Clinical Trials · NCT03870919

Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

Name: Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Active Not RecruitingN/AGonadorelin

Phase: N/A
Recruitment status: Active Not Recruiting
Sponsor: UNICANCER
Enrollment: 200
Start date: Oct 2019
Locations: 26 sites, France
Primary endpoint: Overall survival rate in patients receiving the letrozole plus palbociclib combination plus locoregional treatment

View Gonadorelin compound reference